ELECTRONIC SUPPLEMENTARY INFORMATION

Plasma Biomarkers of Pulmonary Hypertension identified by Fourier Transform Infrared Spectroscopy and Principal Component Analysis

Emilia Staniszewska-Slezak\textsuperscript{a,b}, Andrzej Fedorowicz\textsuperscript{b}, Karol Kramkowski\textsuperscript{c}, Agnieszka Leszczynska\textsuperscript{c}, Stefan Chlopicki\textsuperscript{b,d}, Małgorzata Baranska\textsuperscript{a,b} and Kamilla Malek\textsuperscript{a,b,*}

\textsuperscript{a}Faculty of Chemistry, Jagiellonian University, Ingardena 3, 30-060 Krakow, Poland.
\textsuperscript{b}Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland.
\textsuperscript{c}Department of Pharmacodynamics, Medical University in Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
\textsuperscript{d}Department of Experimental Pharmacology (Chair of Pharmacology), Jagiellonian University, Grzegorzecka 16, Krakow, 31-531, Poland.
Figure S1. Raw FTIR spectra extracted from IR images for: control of systemic hypertension (A) and systemic hypertension (B).
**Figure S2.** FTIR images constructed from integration of the amide I band for a control plasma sample: (A) before and (B) after quality test. Color false scale indicates absorbance of the band.
Figure S3. Second derivative FTIR spectra for control and PAH groups before (A) and after (B) Extended Multiplicative Signal Correction (EMSC).
Figure S4. PCA analysis for systemic hypertension (green squares) versus control (blue dots) in the 3100-2800 and 1800-900 cm\(^{-1}\) range showing three-dimensional score plot along PC-1, PC-2 and PC-3 (A) and three-dimensional score plot along PC-1, PC-2 and PC-4.